During the past decade, Emory University conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 6 clinical trials were completed, i.e. on average, 60% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 3 clinical trials were completed. i.e. 300% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Emory University" #1 sponsor was "BioMarin Pharmaceutical" with 9 trials, followed by "Shire" with 3 trials sponsored, "Emory University" with 2 trials sponsored, "Nadia Ali, PhD" with 2 trials sponsored and "Actelion" with 2 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Emory University" #1 collaborator was "BioMarin Pharmaceutical" with 3 trials as a collaborator, "Genentech, Inc." with 1 trials as a collaborator, "ICON plc" with 1 trials as a collaborator, "Lysosomal Disease Network" with 1 trials as a collaborator and "National Center for Advancing Translational Sciences (NCATS)" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Emory University" are "Achondroplasia" (4 trials), "Phenylketonuria" (4 trials), "Fabry Disease" (2 trials), "Morquio A Syndrome" (2 trials) and "Morquio Disease" (2 trials). Many other conditions were trialed in "Emory University" in a lesser frequency.

Most popular intervention types in "Emory University" are "Drug" (13 trials), "Other" (3 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "BMN 111" (2 trials), "Kuvan" (2 trials), "Placebo" (2 trials), "AGT-182" (1 trials) and "Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily." (1 trials). Other intervention names were less common.

The vast majority of trials in "Emory University" are 21 trials for "All" genders, 2 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Emory University". undefined are not yet recruiting, undefined are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 17 completed trials in Emory University, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Emory University, 1 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".